IMAXIO

IMAXIOis a lyonbiopole member

General information

99, rue de Gerland

69007 Lyon

Incorporated in: 2000/09/08

Number of employees: 14

Turnover: €2M (in 2017)


More information

 

Main activity

Founded in 2000, IMAXIO is a biotech company specializing in the field of vaccinology. Owing to his significant scientific and commercial expertise, IMAXIO is active in all stages of the life cycle of vaccines, from development through to market release. IMAXIO is specialised in the prevention of human leptospirosis. IMAXIO has an international business presence, particularly in Asia where the company maintains a partnership for the distribution of the leptospirosis vaccine, and plans to extend its activities into new markets, most notably in Europe via a number of distribution partnerships. For the French market, IMAXIO is open to the establishment of agreements for distribution and product purchasing licenses, whether in the fields of workplace health and safety or travel-related illness.


Funding

Looking for funding: Yes

Private funding obtained: Pradeyrol Développement

Public funding obtained: BPI France and COFACE

Segmentation
Activities
Products / Services / Technologies
Partnership opportunities / Licensing

Strategic area of application
Human Medicine


Application market
Infectiology - Parasitology


Activities
Therapeutics, Pharma or Biotech


Technologies
Vaccine

By continuing your navigation on our site, you accept the use of cookies and the collection of your data and personal information by Lyonbiopôle, for the purposes of measuring the traffic on the website, to provide statistics and to offer you adapted content to your centers of interest. To exercise your rights of access, rectification, opposition, deletion and portability, in accordance with the General Data Protection Regulation (EU 2016/679), you are informed that you can send your request to dpo@lyonbiopole.com. More details are available by clicking here I agree